Thank you Nasdaq for shinning a light today on Adaptive Phage Therapeutics and the significant market potential of our phage therapy in meeting the rapidly expanding un-met need for a cure for patients with antibiotic resistant bacterial infections. Thanks to the NEXT team at Shulman Rogers for your support!